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ARTICLE
Structures of the wild-type MexAB–OprM tripartite
pump reveal its complex formation and drug efflux
mechanism
Kenta Tsutsumi 1, Ryo Yonehara1, Etsuko Ishizaka-Ikeda1, Naoyuki Miyazaki 1, Shintaro Maeda1,2,
Kenji Iwasaki1,3, Atsushi Nakagawa 1 & Eiki Yamashita 1
In Pseudomonas aeruginosa, MexAB–OprM plays a central role in multidrug resistance by
ejecting various drug compounds, which is one of the causes of serious nosocomial infec-
tions. Although the structures of the components of MexAB–OprM have been solved
individually by X-ray crystallography, no structural information for fully assembled pumps
from P. aeruginosa were previously available. In this study, we present the structure of wild-
type MexAB–OprM in the presence or absence of drugs at near-atomic resolution. The
structure reveals that OprM does not interact with MexB directly, and that it opens its
periplasmic gate by forming a complex. Furthermore, we confirm the residues essential for
complex formation and observed a movement of the drug entrance gate. Based on these
results, we propose mechanisms for complex formation and drug efflux.
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Gram-negative bacteria have a strong outer membraneconsisting of lipid-bilayer and peptidoglycan in additionto an inner membrane, and they express several types
of tripartite efflux pumps that penetrate both membranes and
release foreign substances1. Multidrug efflux pumps of the
resistance–nodulation–cell division (RND) superfamily, which
are expressed specifically in Gram-negative bacteria, consist of
an RND transporter that penetrates the inner membrane and
plays a major role in drug efflux via a proton gradient; an outer
membrane factor (OMF) that penetrates the outer membrane
and secures the efflux route for drugs; and a membrane fusion
protein (MFP) that is anchored to the inner membrane and
connects the RND transporter and OMF2,3. Overexpression of
RND-type multidrug efflux pumps is a primary cause of multi-
drug resistance4. Pseudomonas aeruginosa, a common Gram-
negative bacterium, causes nosocomial infections and has
particularly high drug resistance5. MexAB–OprM, the only con-
stitutively expressed pump in P. aeruginosa, is thought to con-
tribute significantly to drug resistance in this species6. The crystal
structures of the three proteins constituting MexAB–OprM,
MexA (MFP), MexB (RND), and OprM (OMF), have already
been solved7–12.
OprM forms a trimer with threefold symmetry, and two coiled-
coils of helices 3 and 4 (H3–H4) and helices 7 and 8 (H7–H8)
in the α-barrel domain form a gate on the periplasmic side.
Because H7–H8 blocks the gate in the crystal structure, it is
thought that the gate opens by interacting with the MFP11. MexA
consists of four domains: the membrane-proximal (MP), β-barrel,
lipoyl, and α-hairpin domains8; it is thought that MexA forms
a hexamer in MexAB–OprM. MexB is composed of three
domains: a transmembrane (TM) domain with 12 α-helices,
a porter domain containing the drug-binding pocket, and a
funnel-like (FL) domain involved in interactions with other
components9. A porter domain further consists of four sub-
domains; PN1, PN2, PC1, and PC2, which translate and rotate
during the transport process, thereby altering drug accessibility.
MexB forms an asymmetric trimer in crystal structure, and it is
thought that each protomer shifts conformational states (Access,
Binding, and Extrusion) during drug efflux, similar to the func-
tional rotation mechanism proposed based on the structure of the
Escherichia coli homolog AcrB13. On the other hand, based on
structural analysis of an RND pump derived from Campylobacter
jejuni14, an distinct efflux mechanism was proposed, suggesting
that the mechanisms of action of RND family members may
have diverged.
AcrAB–TolC, a major RND-type multidrug efflux pump in E.
coli, has been extensively investigated, and its structure was solved
by cryo-electron microscopy (cryo-EM)15,16. These studies
revealed that OMF and the RND transporter do not directly
interact. Furthermore, recent work revealed the asymmetric
structure of AcrAB–TolC with closed or open TolC at medium
resolution, as well as the symmetric structure of open
AcrAB–TolC in the presence of inhibitor, at near-atomic reso-
lution17. Based on these structures, it was suggested that
AcrAB–TolC initially forms a complex in the closed state, and
then TolC opens via rearrangement of the AcrA hexamer induced
by a conformational change in AcrB. These studies used geneti-
cally engineered or disulfide linked MFP-RND fusion proteins for
structural analysis. Although 3D structure of MexAB–OprM
using a negative-stain method was reported previously18, no
(near-) atomic resolution structure of a multidrug efflux pump
derived from P. aeruginosa has been elucidated to date. Here,
we report a structure of the wild-type multidrug efflux pump
MexAB–OprM from P. aeruginosa at near-atomic resolution,
in the presence or absence of drug. Based on a structural com-
parison, we propose a mechanism for complex formation, as well
as a mechanism for drug release that differs from previously
proposed mechanisms for RND-type multidrug efflux pump
complexes.
Results
Structural determination and overall structure of
MexAB–OprM. Fully assembled MexAB–OprM pump was pre-
pared by in vitro reconstruction method (Supplementary Fig. 2).
The detergents used in each preparation of MexB and OprM
were replaced with amphipol A8–3519. The three-dimensional
(3D) structure of MexAB–OprM was determined by cryo-EM
single-particle analysis (Supplementary Fig. 3a). During this
analysis, we identified two modes of binding of OprM to MexA;
accordingly, we determined the structures of both states of
MexAB–OprM pumps at resolutions of 3.64 Å (state A) and
3.76 Å (state B). These maps are of sufficient quality to Cα-trace,
and we could identify orientations of almost all of bulky side
chains (Supplementary Figs. 3, 10).
The overall structure of MexAB–OprM is a vertically elongated
rod shape, ~320 Å along the long axis and ~110 Å along the
short axis, and the stoichiometry of OprM, MexA, and MexB is
1:2:1 (Fig. 1). MexB does not directly contact OprM; instead,
MexA joins MexB and OprM by forming a funnel-like hexamer.
Among the four domains of MexA, only the α-hairpin domain
interacts with OprM; the β-barrel domain interacts with the
FL domain of MexB, and the MP domain interacts with the
porter domain of MexB. The lipoyl domain of MexA does not
connect with either OprM or MexB, but it forms a hexameric
ring along with the β-barrel domains. MexA protomers are
divided into two classes according to the area of their interaction
surface with MexB: the large-contact (LC) protomer (~1450 Å2)
and the small contact (SC) protomer (~950 Å2). The MP domains
of the LC protomers are located in the PC1 domains of each
MexB protomer (Fig. 1, colored by orange), whereas the MP
domains of the SC protomers were located between each
protomer of MexB (Fig. 1, colored in magenta). Each protomer
of MexB is in one of three different states in the crystal structure
(Supplementary Fig. 7). On the other hand, the periplasmic gate
of OprM is opened and the drug efflux route is secured unlike
the crystal structure. State A and state B are quite similar (Cα
RMSD: 0.47); however, the relative positions of OprM in each
state are related by a 60° rotation. Hereafter, we denote state A
as the 0° state and state B as the 60° state.
Interaction between OprM and MexA. Local resolution valida-
tion shows that the contact face region between OprM and
MexA has ~3 Å resolution, which allows us to fit good atomic
models into the maps (Supplementary Fig. 3e, h). In the 0° state,
H3–H4 of OprM face the α-hairpin tips of the LC protomers,
whereas H7–H8 face the α-hairpin tips of the SC protomers.
In the 60° state, on the other hand, H3–H4 of OprM face the
α-hairpin tips of the SC protomers, and H7–H8 face the α-hairpin
tips of the LC protomers (Figs. 1 and 2). The Cα RMSD between
periplasmic tips of the OprM protomer in two states
(S188–E214: H3–H4; Y396–F422: H7–H8) is 1.1 Å, and the Cα
RMSD between α-hairpin domains of hexameric MexA in
two states (A74–F134) is 0.33 Å. The contact surface areas
between the MexA hexamer and OprM trimer are 2992 Å2
(0° state) and 2983 Å2 (60° state). Several hydrogen bonds are
present between main chains: Q104 in MexA binds to A203 or
Y411 in OprM, and K108 in MexA binds to G199 or G407 in
OprM (Fig. 2a, b; Supplementary Fig. 11). Also, L100 in MexA
engages in hydrophobic interactions with V198 and V200 on
H3–H4 or V408 on H7–H8. Moreover, the side chain of R403
in OprM extends inward from H7 and seems to form a hydrogen
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bond with the main chain of A105 in MexA. These results suggest
that the two modes of binding between MexA and OprM do not
differ significantly. In addition, the number of particles in the 3D
classification of both states was not much different (Supple-
mentary Fig. 3), and it might be considered that these two
binding modes exist equally within bacterial cells.
Regarding the interaction between OprM and MexA, several
residues that were thought to be important for interactions, as well
as a few models of complex formation, have been proposed based
on previous mutation experiments and molecular dynamics (MD)
simulations of tripartite efflux pumps20–25. To identify the residues
involved in complex formation, we performed a functional analysis
a b c d
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90°
Fig. 1 Overall structure of MexAB–OprM. Single-particle cryo-EM reconstruction (top) and model of MexAB–OprM (bottom) in the 0° state (a) or 60°
state (b) viewed from the periplasmic space (a, b) or from the outside the cell (c, d). The OprM protomers are colored in cyan, salmon, and lemon. MexA
protomers are colored in magenta (SC protomer) or orange (LC protomer). MexB protomers in the Access, Resting, and Extrusion states are colored
in green, blue, and red, respectively
H3-4 H7-8
MexA
OprM
Y411
Q104
L100
R96
S107
K108
V198
Q104
L100
L100
S107
K108
R96
G199
V200
G407
V408
R403
A203
R96
S107
A105
H3-4
H7-8
MexA
OprM
Y411
Q104
L100
R96 S107
K108
V198
Q104
L100
L100
S107
K108
R96
G199
V200 G407
V408
R403
A203
R96
S107 A105
0° 60°ba
Fig. 2 Interaction between OprM and MexA. Close-up views of the α-hairpin of OprM (shown in lemon) and the α-hairpin of MexA [shown in magenta
(SC protomer) or orange (LC protomer)] in the 0° state (a) or 60° state (b). Previously proposed RLS motifs are shown as balls colored in cyan (R96),
gray (L100), and yellow (S107)
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for residues previously proposed to be required21,24,25 or that
seemed important based on our cryo-EM structure. Specifically, we
performed in vitro complex formation analysis using site-point
mutation and size exclusion chromatography (SEC) (Supplemen-
tary Fig. 5) and conducted experiments to determine the in vivo
drug resistance (Supplementary Fig. 6). Alanine mutations for
G199 and G407 in OprM, which were proposed to be critical
residues in a previous study24, completely abolished complex
formation. These glycine residues are located at equivalent
positions between the H3–H4 and H7–H8 loops, and the main
chains of these glycine residues and the K108 residue of MexA
were at a distance suitable for formation of a hydrogen bond
(Fig. 2). Aspartate mutation of the L100 residue of MexA, one of
the RLS motifs proposed to be important for complex formation
of MFP based on structural analysis of AcrAB–TolC16,21, also
completely abolished complex formation and drug resistance
(Supplementary Fig. 5c, 6). By contrast, aspartate mutation of the
adjacent residue L99 had no effect on complex formation,
highlighting the importance of L100. Because L100 contacts H3
or H7 of OprM from the side, and its side chain is close to V200
on H3 or V408 on H7 (Fig. 2), we speculated that L100 binds
MexA and OprM via hydrophobic interactions. R403 of OprM,
not previously proposed to be important, was critical for complex
formation: alanine mutation at this position abolished complex
formation (Supplementary Fig. 5d). S107 in MexA, one of the RLS
motifs, was also proposed to be an important residue based on
MD simulation25. Although aspartate mutation of this residue
disrupted complex formation and decreased drug resistance in the
drug-resistance assay, we could confirm no specific interaction of
S107 in our structure. The side chain of S107 is located at the
narrow gap between MexA tip and OprM tip (4–5.5 Å), so the
inhibition of complex-formation ability by the aspartate mutation
is thought to be due to steric hindrance of the side chain. Like L100
and S107, the remaining RLS motif, R96, is also conserved, but its
alanine mutants formed a complex as efficiently as the wild-type.
By contrast, aspartate mutation at this residue decreases its
minimum inhibitory concentration experiments21, consistent with
our experimental results of the drug-resistance assay (Supplemen-
tary Fig. 6), and also diminished complex formation. Based on
these results, we can conclude that R96 in MexA is not essential for
complex formation, and that the decrease in complex-forming
ability caused by the aspartate mutation was due to charge
repulsion. Furthermore, D103 and Q104 in MexA were predicted
to be important for complex formation based on previous MD
simulations25; however, alanine mutations of these residues did
not show significant effects in either in vitro or in vivo functional
analysis (Supplementary Fig. 5c, 6). Therefore, the tip-to-tip
interaction of MexA and OprM is based mainly on the interaction
between the main chains, such as Q104–A203 or –Y411 and the
aforementioned K108–G199 or –G407 (Fig. 2). In addition, the
interactions between the side faces of OprM and MexA, such as
the hydrophobic interaction centering on L100 in MexA or the
hydrogen bond between the side chain of R403 in OprM and the
main chain of A105 in MexA, are also essential for complex
formation.
Interaction between each MexA protomer. Except for the MP
domains, the MexA hexamer has C6 symmetry, and is formed by
arrangement of the β-barrel domains in a ring shape via elec-
trostatic interactions (area of contact surface: 1254 Å2). For
example, R39 or R147 interacts with E152 or E226 of the adjacent
protomer (Fig. 3a). Repelling charge mutations (R39D or R147D)
prevented complex formation, as determined by SEC experiments
(Supplementary Fig. 5b), and decreased drug resistances in the
drug-resistance assay (Supplementary Fig. 6). The hexameric
assembly in the lipoyl and β-barrel domains were similar to those
in MacA, an MFP of the ABC-type multidrug efflux pump
MacAB–TolC in E. coli, which forms hexamer in the single-
crystal structure26 and in the tripartite complex27.
Interaction between MexA and MexB. MexA and MexB have
two interacting faces: the β-barrel domain of MexA with the FL
domain of MexB and the MP domain of MexA with the porter
domain of MexB. The interaction area between the β-barrel and
FL domains is about 600 Å2, and did not differ significantly
between the SC and LC protomers. However, the area of the MP
domain and porter domain was significantly different: ~360 Å2
for the SC protomer vs. ~860 Å2 for the LC protomer. Note that
there is little difference in these interactions regardless of the
states of MexB.
For complex formation between the SC protomer and MexB,
we observed two specific interactions in our cryo-EM structure.
The key loop (L252–V260), located at the top of the FL domain
of MexB, shifts onto the side of the adjacent protomer in
comparison with the crystal structure, and sticks in the hollow
formed by the β-barrel domain of the SC protomer (Fig. 3b). The
side chains of R34 and T233 in this hollow are positioned at a
distance suitable for formation of a hydrogen bond, with the
carbonyl groups of P255 or N254 and S258 located in the key
loop. In addition, the side chain of R277 in the MP domain is
about 3–4 Å from the side chain of E244 in MexB, sufficient to
form a hydrogen bond (Fig. 3c). Indeed, the alanine or aspartate
mutant of R34 or R277, as well as the alanine or valine mutant
of T233, lost the ability to form a complex (Supplementary
Fig. 5a, e). These mutations also decreased drug resistance, as
determined by the drug-resistance assay (Supplementary Fig. 6).
Therefore, we can conclude that these three residues are essential
for SC protomer binding. On the other hand, in the LC protomer,
the entire MP domain faces PC1 of MexB, forming an interaction
across the entire plane (Fig. 3d). PC1 undergoes no conforma-
tional change relative to the crystal structure except for a shifted
helix (M653–A661), which was pushed out by F328 in the LC
protomer (Fig. 3e).
Comparation of the closed and open structures of OprM. In the
crystal structure of isolated OprM (PDB ID: 3d5k; https://doi.org/
10.2210/pdb3D5K/pdb), the periplasmic gate is closed by the
hydrophobic interaction of L412 between the protomers and the
salt bridge between D416 and the adjacent R41912. In the proto-
mers, the side chains of S188 and T192 on H3 form a hydrogen
bond with R405 on H7. In our cryo-EM structure, H3–H4 opens
~9° compared with the crystal structure with T178 and Q222
acting as the fulcrum, and the hydrogen bonding with the side
chain of R405 disappeared (Fig. 4a, b; Supplementary Movies 1, 2).
Also, H7–H8 rotated ~19°, with R376 and R432 as the fulcrum.
Consequently, the Cα atom of L412 moved 11.4 Å outward, and
the salt bridge between R419 and D416 disappeared.
The crystal structure and cryo-EM structure of MexB. In our
structures, MexB is asymmetric: specifically, the structures of
the FL domain (excluding the key loop) and the TM domain
were very similar to the Access, Bind, and Extrusion states in the
previously reported crystal structures (Supplementary Fig. 7). By
contrast, with respect to the porter domain, although the Access
and Extrusion states are very similar, except for shifted helixes, a
slight difference can be observed in the protomer corresponding
to the Bind state. Compared with the crystal structure, PC2 is
shifted by ~3 Å toward PC1 and the cleft between PC1 and PC2
does not exist (Fig. 5a, b). Also, because PC2 approaches PC1, the
gate loop (G675–F680) connecting PC1 and PC2 is bent upward,
and N676 interacts with F617 on the switch loop (Fig. 5a). Note
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that a similar interaction is observed in the Extrusion state in the
MexB crystal structure. Consequently, in the cryo-EM structure,
all three MexB protomers are closed toward the outside, repre-
senting a state that cannot accommodate drug molecules. Based
on this evidence, we concluded that this is a resting state, in
which drug efflux does not occur.
MexAB–OprM in the presence of drug. To determine how the
presence of drug affects the structure of MexAB–OprM, we added
novobiocin, an aminocoumarin antibiotic, to the sample to create
a grid for cryo-EM. Data collection and single-particle analysis
were performed in the same manner as for the drug-free state,
and maps with resolutions of 3.5 Å (0° state) and 3.6 Å (60° state)
were acquired (Supplementary Fig. 4). Overall, each structure is
very similar to the corresponding drug-free structure, with large
differences only at the gate loop and the PC2 domain of the Bind
protomer of MexB. In the presence of novobiocin, the corre-
sponding MexB protomer is similar to the crystal structure;
the PC2 opened outward, the cleft between the PC1 and the
PC2 opened, and the gate loop was stretched and descended. In
addition, a density corresponding to novobiocin appears in the
distal binding pocket (Supplementary Fig. 8).
Discussion
In our cryo-EM structure, OprM exhibits two types of binding
states in both the presence and absence of the drug. When OprM
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Fig. 3 Detailed views of the MexA–MexA and MexA–MexB interactions. a Detailed view of the lipoyl domains of MexA [shown in magenta (SC protomer)
or orange (LC protomer)]. Side chain atoms of residue pairs identified in our model of complex formation are shown as stick models. b Close-up view of the
interaction between the FL domain in MexB (green) and the SC protomer (magenta). The key loop in the crystal structure (PDB ID: 3w9i) is shown in
transparent lemon. Side chain atoms of critical residues identified in the complex formation experiment are shown as stick models. c Interaction between
the porter domain of MexB (green) and the SC protomer (magenta). d, e Interaction between the PC1 domain (green) and LC protomer (orange) viewed
from the side of PC1 (d) or top of PC1 (e). The adjacent MexB protomer is shown in red. The shifted helix from the crystal structure of MexB in the Access
state is shown in gray. Red arrows show a movement of shifted helix
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states were separated in single-particle analysis, the ratio of par-
ticles in the 0° versus 60° states was 45:55 (in the absence of
drug) and 58:42 (in the presence of novobiocin), suggested an
overall ratio of nearly 1:1. MexB, which is embedded in the inner
membrane, and MexA, which is anchored to the inner mem-
brane, can move freely on the inner membrane, whereas OprM,
which penetrates the hard outer membrane and peptidoglycans28,
is remarkably restricted in terms of movement and rotation. The
presence of two binding modes in OprM is likely to increase
the chances of contact between MexA and OprM.
In the crystal structure of OprM alone, the periplasmic gate is
closed, whereas in the complex structure obtained by cryo-EM,
the gate is open. Previous study showed that MexAB is required
for opening OprM29. Based on our native complex structure and
mutagenesis experiments, we propose the following mechanism
by which OprM opens while binding MexA:
The side face of the H3 helix in OprM and residue L100 in
MexA clash when the crystal structure of OprM and the cryo-EM
structure are superposed (Fig. 4a). Because our functional ana-
lyses showed that L100 is essential for complex formation, and
H3–H4 opens slightly outward in the cryo-EM structure, clash
between L100 and H3–H4 may be responsible for the initial
movement. After H3–H4 is pushed out by L100, and the tip of
H3–H4 interacts with the confronting α-hairpin tip of MexA
(Fig. 4c, top centre). Subsequently, hydrogen bonds between H3
and H7 (S188 or T192–R405) in the protomer are broken by
opening H3–H4 (Fig. 4c, top right). Meanwhile, H7–H8 becomes
unstable, causing the hydrophobic interaction of L412 and the
D416–R419 salt bridge between protomers to be broken; conse-
quently, H7–H8 starts to rotate dramatically (Fig. 4c, bottom left).
This rotation is stopped by a side interaction with MexA, which
is fixed by a tip-to-tip interaction with H3–H4 on the left adjacent
protomer (due to a hydrophobic interaction of L100 in MexA or
the hydrogen bond between A105 in MexA and R403 in OprM).
Finally, by interacting with the side of H3–H4, a tip-to-tip
interaction forms between H7–H8 and the fixed MexA α-hairpin
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Fig. 4 A model of OprM channel opening. a, b Superposition of the OprM crystal structure (PDB ID: 3d5k, gray) and cryo-EM structure (0° state, colored
according to Fig. 1) viewed from the periplasmic space (a) or from outside the cell (b). Red arrows indicate helix movements of H3–H4 or H7–H8 from the
closed crystal structure to the open cryo-EM structure. c Schematic cartoon of the channel-opening mechanism of OprM. Enclosed letters with circles
indicate critical residues for channel opening and complex formation: L indicates L100 in MexA, and S, T, and R indicate S188, T192, and R405 in OprM,
respectively
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(Fig. 4c, bottom right). As a result, OprM with a fully opened
periplasmic gate is formed. The opened and closed structures of
AcrAB–TolC from E. coli have been reported17. Although we
could not observe a closed complex in our single-particle analysis,
the structures of both MexAB–OprM and AcrAB–TolC in which
OMF are opened are quite similar and previous studies show that
MexB can form a chimeric complex with AcrA and TolC18,30,31,
therefore, the mechanism of opening the OMF might be similar
in both AcrA–TolC and MexA–OprM.
Based on the results of this study, we propose a mechanism for
MexAB–OprM complex formation and a model for drug efflux,
as follows. In the complex-formation experiment, SEC peak shifts
were observed for MexA and MexB, but not for MexA and OprM
or OprM and MexB (Supplementary Fig. 9), suggesting that the
MexA–MexB complex is more stable than MexA–OprM complex
and MexA might form a complex with MexB prior to OprM.
MexA is sequentially bound by MexB via interactions between the
MP and β-barrel domains in MexA and the FL domain in MexB,
and the bound MexA engages in mutual interactions between
lipoyl domains to form a hexameric ring, resulting in formation
of the MexA–MexB intermediate (Fig. 6a). When OprM comes in
contact with the ring formed by the α-hairpin domain of the
MexA hexamer, MexA L100 clashes with the H3 helix in OprM,
and the H3–H4 helix is pushed outward (Fig. 6b). After that, as
described above, the H7–H8 helix rotates, the interaction between
the OprM trimer and the MexA hexamer is completed, and the
periplasmic gate opens (Fig. 6c, d). When the surrounding drug
concentration becomes high, the gate loop of MexB shifts
downward, and the binding pocket is opened to the molecular
surface. After that, MexB ejects drugs into the tunnel of
MexA–OprM via a functional rotation mechanism. When the
concentration of drugs in this tunnel becomes higher than their
concentration outside the cell, they diffuse out of the cell via the
concentration gradient (Fig. 6e). As the concentration of drug in
the cell decreases, the drug entrance of the binding protomer
of MexB is closed by the structural change of the gate loop, and
the complex shifts from the Binding state to the Resting state.
Under these conditions, because the pump is completely closed to
the periplasm, backflow of drugs is prevented. When the con-
centration of drug in the environment rises, the resting protomer
again undergoes a structural change to the Binding state, and
drugs are taken in and released. This study provides insights into
RND-type multidrug efflux pump; however, these results were
based on snapshots of the pump in a particular conformation.
Therefore, further dynamic structural study such as MD simu-
lation might be needed for verifying our proposed mechanism.
Methods
Expression and purification of MexA, MexB, and OprM. MexA, MexB, and
OprM were expressed and purified as previously described7,9,11, with slight
N676
F617PC2
TM
PC1
a
b c d
Fig. 5 Conformational change of MexB from the Resting state to the Binding state. a Superposition of the Resting state in the cryo-EM structure (blue), the
Binding state in the crystal structure (PDB ID: 3w9i, gray), and the Binding state in the cryo-EM structure (cyan). Gate loops are colored in red. Red arrows
indicate conformational changes of the gate loop. b–d Visualization of channels to the distal binding pocket, generated using caver v. 3.0.145. Shown are
the Resting state in the cryo-EM structure (b), the Binding state in the crystal structure (c), and the Binding state in the cryo-EM structure (d). Channels
are shown as yellow spheres with diameters greater than 1.6 Å (top panels) and 2.0 Å (bottom panels). Atomic models are shown in ribbon diagram,
and surface views are transparent with the same color as in a. Gate loops are colored in red
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modifications. All the primers used for cloning are listed in Supplementary Table 2.
The gene encoding MexA (a.a., 2–360), which lacks the region containing the signal
peptide and the first cysteine, was cloned into pET28 (b+) vector with an N-
terminal 6xHis-tag followed by a TEV-protease cleavage site. The resultant plasmid
was transformed into BL21-RILP(DE3) (Stratagene, Supplementary Table 3). The
bacterial cells were cultured in the LB medium, and the protein expression was
induced with 0.4 mM IPTG. Collected cells were suspended in buffer A (50 mM
Na-phosphate [pH 7.4], 300 mM NaCl) supplemented with 10 mM imidazole and
1 µM phenylmethylsulfonyl fluoride (PMSF), and then disrupted by sonication and
centrifuged at 39,000 g for 30 min. The supernatant was purified with Ni-NTA
(QIAGEN), which was eluted with 250 mM imidazole. The 6xHis-tag was removed
with TEV-protease, and the de-tagged sample was subjected to a Superdex200
16/60 column (GE healthcare) with buffer B (20 mM Na-phosphate [pH 7.4],
150 mM NaCl). Peak fractions were concentrated to ~50 mgmL−1 using a
VIVASPIN 20 mL (10,000 MWCO).
The gene encoding full-length MexB was cloned into pET22 (b+) vector with a
C-terminal 6xHis-tag, and the resultant plasmid was transformed into C43(DE3)
(OverExpress, Supplementary Table 3). The bacterial cells were cultured in the TB
medium, and protein expression was induced with 1.2 mM IPTG. Collected cells
were disrupted in a French press (SMT CO., LTD.), and debris was removed by
centrifugation at 10,000 g for 10 min at 4 °C. Membrane fractions were collected by
ultracentrifugation at 235,000 × g for 1 h at 4 °C (45 Ti rotor, Beckman). Collected
membrane fractions were washed with high-salt buffer (50 mM Na-phosphate
[pH 7.4], 1 M NaCl), and then collected by ultracentrifugation. This wash step
was repeated three times. The washed membranes were resuspended in buffer A
supplemented with 30% (v/v) glycerol, flash frozen in liquid nitrogen, and stored
at −80 °C. Thawed membranes were suspended in buffer A, and then 1% (w/v)
n-dodecyl-β-D-maltoside (DDM, Anatrace) was added for additional washing.
After ultracentrifugation at 164,000 × g for 1 h at 4 °C (SW32 Ti rotor, Beckman),
soluble impurities were discarded. The precipitate was resuspended in buffer A
and supplemented with 2% (w/v) DDM and 40mM imidazole (pH 7.4). The
mixture was stirred at 4 °C for 1 h, and the insoluble fraction was removed by
ultracentrifugation, as described above. The soluble fraction was subjected to
Ni-chelating Sepharose (GE Healthcare) in an Econo-column (Bio-Rad). The
resin was washed with buffer A containing 150 mM imidazole and 0.1% (w/v)
7-cyclohexyl-1-heptyl-β-D-maltoside (CYMAL-7, Anatrace), and then purified
MexB was eluted with buffer A containing 350 mM imidazole and 0.02% CYMAL-
7. Eluted samples were gathered, concentrated using a SPIN-X 20 mL (100,000
MWCO), and subjected to a Superdex200 16/60 column with buffer C (buffer
B supplemented with 0.02% CYMAL-7). Peak fractions were concentrated to
~25 mgmL−1.
The gene encoding full-length OprM was cloned into pET21(b+) vector with a
C-terminal 6xHis-tag, and the resultant plasmid was transformed into C43(DE3).
The bacterial cells were cultured in 2x YT medium, and the protein expression
was induced with 1.2 mM IPTG. Disruption, membrane fractionation, and first
wash were performed as described above for MexB. The inner membrane fraction
was solubilized with 2% (v/v) Triton X-100 at 4 °C for 20 min. Solubilized inner
membrane was removed by ultracentrifugation, and then washed once with 50 mM
Na-phosphate [pH 7.4] supplemented with 5% glycerol. The washed membranes
were resuspended with buffer A supplemented with 30% (v/v) glycerol, flash frozen
in liquid nitrogen, and stored at −80 °C. Thawed membranes were suspended
with buffer A supplemented with 2.5% n-octyl-β-D-glucoside (OG, Anatrace) and
imidazole (pH 7.4) to 20 mM. The mixture was stirred at 4 °C for 1 h, and the
insoluble fraction was removed by ultracentrifugation at 235,000 × g for 1 h at 4 °C
(50.2 Ti rotor, Beckman). The soluble fraction was subjected to Ni-NTA in an
Econo-column. The resin was washed with buffer A containing 40 mM imidazole
and 0.1% CYMAL-7, and then purified OprM was eluted with buffer A containing
250 mM imidazole and 0.02% CYMAL-7. Eluted fractions were gathered and
subjected to a Superdex200 16/60 column with buffer C. Peak fractions were
concentrated to ~10 mgmL−1 using a SPIN-X 20mL (100,000 MWCO).
Reconstruction of MexAB–OprM. Purified MexA, MexB, and OprM were mixed
at a molar ratio of 3:1:1 in buffer C, and the mixture was dialyzed against buffer D
(20 mM Na-citrate, 300 mM KCl, 0.02% CYMAL-7) at 4 °C. We note that we used
excess MexA to improve the efficiency of reconstitution. Unreconstructed proteins
were removed by SEC on a Superdex200 16/60 column in buffer D. Peak fractions
were concentrated with a SPIN-X 20 mL (100,000 MWCO).
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Fig. 6 Proposed model for complex formation and drug efflux by MexAB–OprM. Sectional views of the MexA–OprM interaction surface section in the
0° state (top panels) and 60° state (middle panels), and views from the periplasmic space of the complex in the 0° state (bottom panels). Each protomer
is colored as in Figs. 1 or 5. a Six MexA protomers bind to the MexB trimer and form a hexameric tube. b The closed OprM trimer interacts with the MexA
hexamer by opening the H3–H4 helixes. c The H7–H8 helixes revolve outward and are trapped against the side of MexA via hydrophobic interactions.
d Formation of the fully opened MexAB–OprM pump is completed. e Depending on the drug concentration, the resting protomer in MexB changes its
conformation, resulting in formation of the Binding state. Drugs are taken into MexB and pass through the MexA–OprM tube, and are then ejected outside
the cell according to their concentration gradients
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Detergents removal and replacement with Amphipol. Reconstructed
MexAB–OprM (~4 mg) was precipitated by mixing buffer D supplemented with
20% (v/v) PEG-3350 at a volume ratio of 1:2 and then centrifuging at 20,400 g for
30 min at 4 °C. After removal of the supernatant, 250 µL of 50 mM HEPES-K
(pH 7.5) containing 20 mg of Amphipol A8–35 (Anatrace) was added to the pellet,
and the sample was incubated at 4 °C for 4 h with gentle rotation. Subsequently,
~125 mg of Bio-Beads SM2 (Bio-Rad) was added to the sample, which was rotated
at 4 °C overnight. The beads were removed with a poly-prep column (Bio-Rad).
The sample was subjected to a Superose6 Increase 10/300 column (GE Healthcare)
with 50 mM HEPES-K (pH 7.5). Peak fractions were concentrated with an Amicon
Ultra-0.5 mL 100 K (Merck Millipore).
EM data acquisition. For the apo-state, 2 µL of sample solution (9.1 mg mL−1) was
applied to a glow-discharged holey carbon film (Quantifoil 1.2/1.3R, 300-mesh Mo
grid). The grid was blotted for 6 s and flash frozen in liquid ethane using a Vitrobot
Mark IV (FEI). The datasets were collected on a Titan Krios G2 (FEI) operated at
300 kV, equipped with an FEI Falcon II direct detector. Images were recorded
at a nominal magnification of ×75,000 (corresponding to a pixel size of 0.875 Å).
Thirty-two frames were recorded for exposure times of 2 s, with defocus value
ranging from −1.25 to −3.0 µm; the total dose was 40 e−Å−2.
For the novobiocin-binding state, the sample (10.2 mg mL−1) was mixed with
100 mM novobiocin in 500 mM HEPES-K (pH 7.5) at a volume ratio of 9:1 1 h
before grid preparation. As a result, the final concentrations of protein and
novobiocin were 9.2 mg mL−1 and 10 mM, respectively. Grids were prepared as
described above for the apo-state. The datasets were collected on a Titan Krios G2
operated at 300 kV, equipped with an FEI Falcon III direct detector (linear mode).
Images were recorded at a nominal magnification of ×59,000 (corresponding to the
pixel size of 1.125 Å). Thirty-two frames were recorded for exposure times of 2 s,
with defocus value ranging from −1.25 to −2.5 µm; the total dose was 40 e−Å−2.
Image processing and 3D reconstruction. Movies were motion-corrected using
MOTIONCORR2 (version 0130217)32 with dose fraction. CTF values were esti-
mated with Gctf (version 1.06)33. The following processes were performed in
RELION-2.034,35. For the apo-state, 8772 micrographs were used for particle
picking (Supplementary Fig. 3). A total of ~20,000 manually picked particles were
subjected to two-dimensional (2D) class averaging to create a reference for auto-
picking. A total of 535,948 particles were extracted from micrographs by auto-
picking, and 2D class averaging was performed to remove false particles. After 2D
classification, the remaining 420,182 particles were subjected to 3D classification
using an initial model created from a previous 3D reconstruction of MexAB–OprM
using data from negative-stained EM single-particle analysis. We performed 3D
refinement on the 174,534 particles remaining after 3D classification. Although the
cryo-EM map of MexAB–OprM at this step had ~4 Å resolution, several ambig-
uous regions, including the upper region of OprM and the PC2 and TM regions of
MexB, were present. To remove ambiguity, we performed sequential local 3D
classification of 155,822 particles, which were subjected to additional whole 3D
classification to remove bad particles. First, we performed local classification of the
OprM–MexA region, enabling separation of the two binding states of OprM (0°
state: 57,499 particles; 60° state: 69,224 particle). Second, we attempted to remove
the ambiguity in the MexB region by local classification, but this approach failed
because of a symmetry mismatch in the α-hairpin domain of MexA (C6 symmetry)
and MexB trimer (pseudo-C3 symmetry). Therefore, we used a symmetry expan-
sion method to apply the correct angles to the particles36: The dataset was enlarged
threefold by adding 0°, 120°, or 240° to the first Euler angle for each particle
(172,347 particles in the 0° state; 207,672 particles in the 60° state), and subjected to
local 3D classification of the MexB region. Finally, particle sets with good homo-
geneity and correct angles were selected judging from the clarity of TM and PC2
(37,971 particles in the 0° state; 42,338 particles in the 60° state). These particles
were subjected to 3D refinement, yielding maps with near-atomic resolution (for
the 0° state, 4.21 Å in unmask and 3.72 Å in mask; for the 60° state, 4.55 Å in
unmask and 3.93 Å in mask). To calculate maps with better resolution, we sub-
tracted the density corresponding to Amphipol and performed a final 3D refine-
ment. This approach yielded improved maps: 4.12 Å in unmask and 3.64 Å in mask
for the 0° state, and 4.17 Å in unmask and 3.76 Å in mask for the 60° state.
For the novobiocin-binding state, we performed single-particle analysis as
described above for the apo-state (Supplementary Fig. 4a). A total of 4681
micrographs were used for particle picking, and 902,901 particles were extracted by
auto-picking. After 2D classification, 659,742 particles remained, and 445,966
particles were subjected to the first 3D refinement after 3D classification. The
calculated map had same ambiguities as the apo-state, so we performed local
classification for OprM–MexA, resulting in separation of the 0° state (230,289
particles) and 60° state (215,677 particles). After symmetry expansion and two
rounds of local classification for the MexB region, good particle sets with 31,409 (0°
state) or 31,466 (60° state) particles were subjected to 3D refinement. In these
refinements, EM maps were calculated for the 0° state at 4.04 Å in unmask and
3.60 Å in mask, and for the 60° state, 4.14 Å in unmask and 3.71 Å in mask. After
density subtraction and final refinement, resolution was improved to 3.95 Å in
unmask and 3.50 Å in mask (0° state) and 4.09 Å in unmask and 3.60 Å in mask
(60° state).
Model building and map sharpening and structural validation. Models of
fully opened OprM trimer and MexA hexamer were prepared using molecular
dynamics flexible fitting (MDFF)37. Closed OprM (PDB ID: 3d5k) was fitted into
the calculated map (apo-state, 0° state) by rigid-body fitting using Chimera38, fol-
lowed by flexible fitting using MDFF. Six MexA protomers (PDB ID: 2v4d; https://
doi.org/10.2210/pdb2V4D/pdb, B chain) were fitted into the map using Chimera,
and subsequently fitted using MDFF. The crystal structure of MexB (PDB ID: 3w9i;
https://doi.org/10.2210/pdb3W9I/pdb) was simply fitted into the map using Chi-
mera. The coordinate files were gathered and subjected to one round of real-space
refinement by phenix.real_space_refine39 and reciprocal space refinement by phe-
nix.refine40. The atomic model that performed this process was used for local B-
factor sharpening of the cryo-EM map using the program locscale41. Final models
were obtained after several rounds of manual correction by coot42 and real-space
refinement against the locally sharpened maps (Supplementary Table 1). Local
resolution validation was performed with ResMap (Supplementary Figs. 3, 4)43. The
pathways for drug efflux in MexB were estimated using caver 3.0.1.
Complex-formation experiment. Plasmids for each mutant were prepared by a
standard PCR method. All the primers used for mutation are listed in Supple-
mentary Table 2. Expression, purification, and reconstruction of each mutant was
performed as described above (Supplementary Fig. 5). Reconstruction experiments
for MexA–MexB, MexA–OprM and MexB–OprM were performed as described
for the reconstruction of MexAB–OprM, except for the omission of OprM, MexB,
and MexA, respectively (Supplementary Fig. 9). The flow-rate of SEC was fixed
at 0.5 mLmin−1.
The in vivo drug-resistance assay. The drug-resistance assay was performed
using a methodology previously described44. The genes of mexA, mexB, and oprM
were subcloned into the pMMB67HE vector. The mutants were prepared with a
standard PCR method. All the primers used for mutation are listed in Supple-
mentary Table 2. The resultant plasmids were transformed into W3104ΔacrABD.
Bacterial cells were cultured overnight in 3 mL of the LB medium supplemented
with 100 µg mL−1 of ampicillin at 37 °C. All of the cultures were adjusted to an
OD590nm of 1.0 with the LB medium and then serially diluted with tenfold dilutions
(10−1–10−6). For each dilution series, 4 µL of each strain was plated onto LB
plates supplemented with 100 µg mL−1 of ampicillin and an additional antibiotic:
none, 5 µg mL−1 of chloramphenicol, 25 µg mL−1 of novobiocin, 5 µg mL−1 of
erythromycin, 0.5 µg mL−1 of minocycline, or 10 µg mL−1 of rhodamine 6 G. All
plates were incubated at 37 °C overnight and then images were recorded.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this manuscript are available from the corresponding
author upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information file. Cryo-EM density maps of the apo-state MexAB–OprM
have been deposited in the Electron Microscopy Data Bank under accession codes EMD-
9695 (0° state), and EMD-9696 (60° state). Atomic coordinates have been deposited in
the Protein Data Bank under accession codes 6IOK (0° state), and 6IOL (60° state).
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